SBIR-STTR Award

  1. You are here:    Home
  2. Search Databases
  3. Search SBIR-STTR Awards
  4. SBIR-STTR Award

Enzyme Therapy For Diseases Involving Active Oxygen
Award last edited on: 11/26/02

Sponsored Program
SBIR
Awarding Agency
NIH : NHLBI
Total Award Amount
$550,000
Award Phase
2
Solicitation Topic Code
-----
Principal Investigator
Abraham Abuchowski

Company Information

Enzon Pharmaceuticals Inc (AKA: Enzon Inc)

20 Kingsbridge Road
Piscataway, NJ 08854
   (732) 980-4500
   investor@enzon.com
   www.enzon.com
Location: Multiple
Congr. District: 06
County: Middlesx

Phase I

Contract Number: 1R43HL035043-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
1985
Phase I Amount
$50,000
Active oxygen species are implicated in many diseases. Enzon is improving the therapeutic effectiveness of superoxide dismutase and catalase by our patented process so that these active oxygen-scavenging enzymes can be used routinely against active oxygen induced or exacer bated pathologies. The improved enzymes are being submitted to a battery of toxicological tests with the objective of obtaining Investigational New Drug numbers for them and initiatin8 clinical studies.National Heart, Lung, and Blood Institute (NHLBI)

Phase II

Contract Number: 2R44HL035043-02A2
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
1988
Phase II Amount
$500,000
The enzyme superoxide dismutase (SOD) has been modified by the covalent attachment of monomethoxypolyethylene glycol (PEG) to form the conjugate PEG-SOD with greatly improved pharmacokinetics and clinically insignifican immunogenicity. Phase I trials have been completed in human volunteers with no adverse effects reported. PEG-SOD will be in evaluated in Phase I clinical trials for three indications: kidney transplants, burns, and multiple trauma. On completion of Phase II trials, we will move to Phase III trials for these indications.National Heart, Lung and Blood Institute (NHLBI)